Serum Angiopoietin-2 Levels Predict the Development of Hepatocellular Carcinoma following Hepatitis C Virus Eradication Using Direct-Acting Antiviral Agents
Oncology · 2024
DOI: 10.1159/000536154 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Takanori Suzuki und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Antiviral Agents, Angiopoietin-2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
Introduction
Our previous studies showed that serum angiopoietin-2 (Ang-2) and C-X-C motif chemokine ligand 10 (CXCL10) levels predicted improvement in liver fibrosis following sustained virological response (SVR) of hepatitis C virus (HCV) obtained with administration of with direct-acting antiviral agents (DAAs). These levels were evaluated retrospectively as predictive indicators of hepatocellular carcinoma (HCC) development following SVR.
Methods
We enrolled individuals from a historical cohort of 89 chronic HCV patients without history of HCC at baseline and with SVR following DAA therapy and had baseline serum levels of Mac-2 binding protein glycosylation isomer ≥2.0 cut-off index (C.O.I.).
Results
Multivariate analyses revealed that only the Ang-2 level at 24 weeks following the end of treatment (EOT24W) was significantly related to HCC development (hazard ratio 2.27; p = 0.003). This result was reproduced in individuals without history of HCC and with advanced liver fibrosis (M2BPGi level ≥3.3 C.O.I. at baseline). Time-dependent receiver operating characteristic curve analyses for the future risk of developing HCC within 5 years of follow-up (5y-HCC) showed the best cut-off Ang-2 level at the EOT24W was 2,780 pg/mL, and significantly stratified the cumulative incidence of HCC (≥2,780 vs. < 2,780 pg/mL, 5y-HCC: 45.5 vs. 8.2%, p < 0.001).
Conclusions
At the EOT24W, serum Ang-2 level predicts the likelihood of developing HCC following SVR to DAA therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Gastroenterology, Kasugai Municipal Hospital, Kasugai, Japan.
- Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Zitieren
APA
Suzuki, T., Matsuura, K., Nagura, Y., Kawamura, H., Fujiwara, K., Ogawa, S., Nagaoka, K., Iio, E., Watanabe, T., Kataoka, H., & Tanaka, Y. (2024). Serum Angiopoietin-2 Levels Predict the Development of Hepatocellular Carcinoma following Hepatitis C Virus Eradication Using Direct-Acting Antiviral Agents. Oncology. https://doi.org/10.1159/000536154
Vancouver
Suzuki T, Matsuura K, Nagura Y, Kawamura H, Fujiwara K, Ogawa S, et al. Serum Angiopoietin-2 Levels Predict the Development of Hepatocellular Carcinoma following Hepatitis C Virus Eradication Using Direct-Acting Antiviral Agents. Oncology. 2024. doi:10.1159/000536154
BibTeX
@article{Suzuki2024,
author = {Suzuki, Takanori and Matsuura, Kentaro and Nagura, Yoshihito and Kawamura, Hayato and Fujiwara, Kei and Ogawa, Shintaro and Nagaoka, Katsuya and Iio, Etsuko and Watanabe, Takehisa and Kataoka, Hiromi and Tanaka, Yasuhito},
title = {Serum Angiopoietin-2 Levels Predict the Development of Hepatocellular Carcinoma following Hepatitis C Virus Eradication Using Direct-Acting Antiviral Agents},
journal = {Oncology},
year = {2024},
doi = {10.1159/000536154}
}
EUVIMED